(LA JOLLA, CA) January 14, 2015–SGI-DNA announces the launch of the Gibson Assembly® Ultra Kit which allows researchers to perform complex, large, and multiple fragment assemblies in a simple, two-step reaction. “With the Gibson Assembly® Ultra Kit, researchers can assemble up to 15 fragments at one time in less than two hours,” says Vibhu Gupta,

(LA JOLLA, CA) November 19, 2014- SGI-DNA announces the launch of the Gibson Assembly® HiFi 1 Step Kit which allows researchers to assemble multiple, large DNA fragments in a simple one hour, one-step reaction. This is the first high fidelity kit on the market using the Gibson Assembly® method. Researchers can now assemble up to

J. Craig Venter, Ph.D., Co-founder and Former CEO, becomes Executive Chairman and Co-Chief Scientist (LA JOLLA, CA) October 27, 2014- Synthetic Genomics, Inc. (SGI), a synthetic biology company commercializing genomic technologies to revolutionize several industries, today announced the appointment of Oliver Fetzer, Ph.D., MBA as the company’s new Chief Executive Officer (CEO). In his role

KEARNY, NJ and LA JOLLA, CA, JUNE 20, 2014 – Avoca, Inc., a division of Pharmachem Laboratories, Inc., has formed a supply agreement with Synthetic Genomics, Inc. (SGI), a privately held company developing and commercializing genomic driven solutions and products in a variety of industries, to extract and commercialize natural astaxanthin from a strain of

LA JOLLA, Calif. and DECATUR, Ill, May 19, 2014 – Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Archer Daniels Midland Company (NYSE: ADM) announced today that the two companies have entered into a long-term agreement to commercialize Omega-3 Docosahexaenoic Acid (DHA) from

Lung Biotechnology Also Makes $50M Equity Investment in SGI LA JOLLA, CA and SILVER SPRING, MD (May 6, 2014) – Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), today announced they have

J. Craig Venter, Ph.D., Founder and CEO, Synthetic Genomics Inc. and Founder and CEO, the J. Craig Venter Institute “Today the United States Supreme Court ruled on the validity of BRAC1 and BRAC2 human gene patents stating that, ‘A naturally occurring DNA segment is a product of nature and not patent eligible merely because it

Program will now focus on utilizing SGI expertise in synthetic genomics to enhance algae LA JOLLA, CA (May 16, 2013)—Synthetic Genomics Inc. (SGI), a privately held company dedicated to developing genomic-driven solutions to address global challenges, today announced a new co-funded research agreement with ExxonMobil to develop algae biofuels. The new agreement is a basic

Design Enables More Rapid Response to Potential Pandemics LA JOLLA, CA and ROCKVILLE, MD—May 15, 2013—A team of international researchers from the J. Craig Venter Institute (JCVI), Synthetic Genomics Inc. (SGI), Novartis Vaccines and Diagnostics, the Biomedical Advanced Research and Development Authority (BARDA, US Department of Health and Human Services), and Institut fur Virologie, Phillips

“In response to a request from the United States Centers for Disease Control (CDC) and Biomedical Advanced Research and Development Authority (BARDA), and after the H7N9 flu virus gene sequences were made publicly available through the Global Initiative on Sharing All Influenza Data (GISAID), the J. Craig Venter Institute (JCVI) and Synthetic Genomics Vaccines, Inc

TOP